Coya Therapeutics enrolled its 100th participant in the Phase 2/3 ALSTARS trial of COYA 302, a combination of low-dose interleukin-2 and CTLA-4 Ig designed to restore regulatory T cell function in amyotrophic lateral sclerosis, with topline data projected for early Q2 2027. Separately published preclinical work on COYA 303, pairing low-dose IL-2 with a GLP-1 receptor agonist, reduced inflammatory markers in blood and brain tissue in mice beyond what either agent achieved alone. Both programs rest on the premise that failed immune self-regulation, rather than neuronal vulnerability alone, drives neurodegenerative progression.
Key Points
- 100th patient enrolled in Phase 2/3 ALSTARS trial of COYA 302
- Low-dose IL-2 plus CTLA-4 Ig restores regulatory T cell function
- IL-2 and GLP-1 agonist reduced brain inflammation synergistically in mice
Longevity Analysis
Regulatory T cell dysfunction sits upstream of the chronic, low-grade inflammation implicated across neurodegeneration, cardiometabolic decline and biological aging generally — making immune self-regulation a target with reach well beyond ALS. The COYA 303 data are particularly notable because GLP-1 receptor agonists, already in widespread metabolic use, appear to act on inflammatory cell populations in brain tissue, suggesting overlapping mechanisms between metabolic and neuroimmune health. Interventions that remove the inflammatory interference before attempting to protect or restore neural tissue represent a sequencing logic applicable far outside rare disease.
Original published by Longevity.Technology, by Kyle Umipig.